莫西沙星联合卷曲霉素治疗耐多药肺结核

Moxifloxacin Combined with Capreomycin in the Treatment of Multidrug-resistant Tuberculosis

目的研究莫西沙星(Moxifloxacin)联合卷曲霉素(Capreomycin)应用于耐多药肺结核(multidrug resistance,MDR-TB)患者的临床疗效及安全性。方法方便选取2019年1月—2020年1月期间在该院接受治疗的104例MDR-TB患者作为研究对象,随机分为对照组(52例)和观察组(52例),在常规基础治疗之上,分别予以单一莫西沙星,以及莫西沙星联合卷曲霉素进行治疗;对比两组患者的治疗效果以及用药安全性。结果观察组治疗总有效率、空洞闭合率分别为96.15%、94.23%,均明显高于对照组(75.00%、73.08%),差异有统计学意义(χ^(2)=9.426、8.509,P<0.05);同时,观察组不良反应发生率(19.23%)略高于对照组(15.38%),差异无统计学意义(χ^(2)=0.269,P=0.604)。结论联合使用莫西沙星及卷曲霉素治疗MDR-TB患者能够在确保用药安全性的前提下提高临床治疗效果,使病灶吸收及空洞闭合速度加快,从而缩短治疗时间,减缓耐药性。

Objective To study the clinical efficacy and safety of moxifloxacin combined with capreomycin in patients with multidrug resistance(MDR-TB).Methods A total of 104 MDR-TB patients who were treated in the hospital from January 2019 to January 2020 were conveniently selected as the research objects,and they were randomly divided into a control group(52 cases)and an observation group(52 cases).On top of this,they were treated with a single moxifloxacin and moxifloxacin combined with capreomycin;the therapeutic effects and drug safety of the two groups of patients were compared.Results The total effective rate and cavity closure rate of the observation group were 96.15%and 94.23%,respectively,which were significantly higher than those of the control group(75.00%,73.08%).The difference was statistically significant(χ^(2)=9.426,8.509,P<0.05);at the same time,the incidence of adverse reactions in the observation group(19.23%)was slightly higher than that in the control group(15.38%),and the difference was not statistically significant(χ^(2)=0.269,P=0.604).Conclusion The combined use of moxifloxacin and capreomycin in the treatment of MDR-TB patients can improve the clinical treatment effect under the premise of ensuring the safety of the medication,accelerate the absorption of the lesion and the closure of the cavity,thereby shorten the treatment time and slow down the drug resistance.